Inhibition of recombinant human PDE5
Biochemical assay · Purified recombinant human PDE5 catalytic domain, amino acids 537–875 [1]
Icariin inhibited cGMP hydrolysis. Sildenafil served as a comparator and activity was normalized to no-drug controls. This endpoint does not establish selectivity or the inhibition mode of native icariin.
| Endpoint | Reported result | Reference |
|---|---|---|
| Inhibition of PDE5-mediated GMP production | IC50 6 ± 1 µM (mean ± SEM; at least three replicates) | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Methods give an assay-wide inhibitor range of 0.001–150 µM; a separate native-icariin dilution series is not listed.
- Exposure duration
- 5 min preincubation followed by 15 min reaction at 25°C
- Method
- HPLC-UV-MS quantification of GMP; 1 nM PDE5 and 0.3 µM cGMP
- Vehicle
- DMSO, maximum 0.1% of final reaction volume
- Reported limits
- Native-icariin-specific concentration series and lot identity are not specified; the >95% purity statement concerns synthesized analogs.
Methods and source locations
Compound reported in the paper: Icariin; Compound label in the paper: icariin
Compound-level preclinical findings; no validation of an Adooq lot or clinical efficacy.
Fig. 3 and caption; Results: Select icariin analogs exhibit enhanced inhibition potencies; Methods: General procedures; Enzyme inhibition and kinetics measurement
Inhibition of PDE5-mediated GMP production: Four-parameter nonlinear regression of activity normalized to no-drug controls. Sildenafil IC50: 0.028 ± 0.007 µM. — Fig. 3 image/caption; Results: Select icariin analogs exhibit enhanced inhibition potencies; Methods: Enzyme inhibition and kinetics measurement